Novartis Drops BeiGene PD-1 Asset Tevimbra As Drug Wins Esophageal Cancer Nod In Europe

BeiGene took back full rights for its PD-1 inhibitor, Tevimbra • Source: Shutterstock

More from Immuno-oncology

More from Anticancer